An analysis of pharmaceutical industry pain points- the case of Portugal

Abstract

This study identifies the problem areas of the pharmaceutical industry in three European countries: Belgium, Italy, and Portugal. It examines the disparities in healthcare systems between the countries and what difficulties they are experiencing in becoming more patient focused. Some issues are common to the countries. Yet, they are weighed differently according to the country's characteristics, mainly economic power. The pharmaceutical industry in Portugal has undergone consistent growth, making substantial contributions to both the nation's economic advancement and healthcare domain. In general, these countries are making progress in prioritizing patients, paving the way for personalized medicines and better disease management. These developments promise substantial benefits in treatment outcomes.